世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

長時間作用型EPO薬の世界市場成長 2023-2029


Global Long-acting EPO Drugs Market Growth 2023-2029

LPI(LPインフォメーション)の最新調査によると、世界の長時間作用型EPO薬の市場規模は2022年に8億2,470万米ドルとなった。下流市場での需要拡大に伴い、長時間作用型EPO薬の再調整後の市場規模は2029年までに1... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年10月8日 US$3,660
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
79 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、世界の長時間作用型EPO薬の市場規模は2022年に8億2,470万米ドルとなった。下流市場での需要拡大に伴い、長時間作用型EPO薬の再調整後の市場規模は2029年までに1億1150万米ドルになると予測され、レビュー期間中のCAGRは4.4%である。
この調査レポートは、世界の長時間作用型EPO治療薬市場の成長可能性を明らかにしています。長時間作用型EPO製剤は今後の市場でも安定した成長が見込まれる。しかし、長時間作用型EPO製剤の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き不可欠です。市場関係者は、長時間作用型EPO製剤市場がもたらす莫大なビジネスチャンスを活用するために、研究開発への投資、戦略的パートナーシップの構築、進化する消費者の嗜好に合わせた製品提供を行う必要がある。
長時間作用型エリスロポエチン(EPO)製剤は、体内の赤血球産生を促進するために使用される薬剤の一種である。これらの薬剤は主に、慢性腎臓病やがん治療に伴う貧血など、特定の病状を持つ人に処方される。
主な特徴
長時間作用型EPO製剤市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、長時間作用型EPO製剤市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(例:エポエチン-アルファ、エポエチン-ベータ)、地域別内訳などが含まれます。
市場促進要因と課題:政府規制、環境問題、技術の進歩、消費者の嗜好の変化など、長時間作用型EPO製剤市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制約、射程距離への不安、初期コストの高さなど、業界が直面する課題も明らかにすることができる。
競合情勢:当調査レポートでは、長時間作用型EPO製剤市場における競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれる。また、新興プレーヤーとその潜在的な市場への影響にもスポットを当てています。
技術開発:本調査レポートでは、長時間作用型EPO製剤業界における最新の技術開発について掘り下げることができます。これには、長時間作用型EPO製剤技術の進歩、長時間作用型EPO製剤の新規参入企業、長時間作用型EPO製剤の新規投資、長時間作用型EPO製剤の将来を形作るその他の技術革新などが含まれます。
川下企業の好み:本レポートは、長時間作用型EPO製剤市場における顧客の購買行動や採用動向を明らかにします。顧客の購買決定や長時間作用型EPO製剤の嗜好に影響を与える要因も含まれる。
政府の政策とインセンティブこの調査レポートは、政府の政策やインセンティブが長時間作用型EPO製剤市場に与える影響を分析しています。これには、規制の枠組み、補助金、税制優遇措置、その他長時間作用型EPO製剤市場の促進を目的とした施策の評価が含まれる。また、市場成長促進におけるこれらの政策の有効性についても評価しています。
環境への影響と持続可能性本調査レポートでは、長時間作用型EPO製剤市場の環境への影響と持続可能性の側面を評価しています。
市場予測と将来展望:実施した分析に基づき、調査レポートは長時間作用型EPO製剤産業の市場予測と展望を提供します。これには、市場規模、成長率、地域別動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、長時間作用型EPO製剤市場の成長と発展に貢献するための潜在的な機会を明らかにしています。
市場の細分化
長時間作用型EPO製剤市場はタイプ別と用途別に分類される。2018年から2029年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額を数量と金額で正確に算出し予測します。
タイプ別セグメント
エポエチン-アルファ
エポエチンベータ
ダルベポエチン-アルファ
その他
用途別セグメント
貧血
腎臓疾患
その他
本レポートは地域別にも市場を分割しています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
アムジェン
ジョンソン・エンド・ジョンソン
協和キリン
本レポートで扱う主な質問
世界の長時間作用型EPO製剤市場の10年見通しは?
世界および地域別にみた長時間作用型EPO製剤市場成長の要因は何か?
市場別、地域別に最も急成長する技術は何か?
長時間作用型EPO製剤の市場機会は最終市場規模によってどのように異なるのか?
長時間作用型EPO製剤のタイプ別、用途別内訳は?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Long-acting EPO Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Long-acting EPO Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Long-acting EPO Drugs by Country/Region, 2018, 2022 & 2029
2.2 Long-acting EPO Drugs Segment by Type
2.2.1 Epoetin-alfa
2.2.2 Epoetin-beta
2.2.3 Darbepoetin-alfa
2.2.4 Others
2.3 Long-acting EPO Drugs Sales by Type
2.3.1 Global Long-acting EPO Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Long-acting EPO Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Long-acting EPO Drugs Sale Price by Type (2018-2023)
2.4 Long-acting EPO Drugs Segment by Application
2.4.1 Anemia
2.4.2 Kidney Disorders
2.4.3 Others
2.5 Long-acting EPO Drugs Sales by Application
2.5.1 Global Long-acting EPO Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Long-acting EPO Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Long-acting EPO Drugs Sale Price by Application (2018-2023)
3 Global Long-acting EPO Drugs by Company
3.1 Global Long-acting EPO Drugs Breakdown Data by Company
3.1.1 Global Long-acting EPO Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Long-acting EPO Drugs Sales Market Share by Company (2018-2023)
3.2 Global Long-acting EPO Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Long-acting EPO Drugs Revenue by Company (2018-2023)
3.2.2 Global Long-acting EPO Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Long-acting EPO Drugs Sale Price by Company
3.4 Key Manufacturers Long-acting EPO Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting EPO Drugs Product Location Distribution
3.4.2 Players Long-acting EPO Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Long-acting EPO Drugs by Geographic Region
4.1 World Historic Long-acting EPO Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Long-acting EPO Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Long-acting EPO Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Long-acting EPO Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Long-acting EPO Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Long-acting EPO Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Long-acting EPO Drugs Sales Growth
4.4 APAC Long-acting EPO Drugs Sales Growth
4.5 Europe Long-acting EPO Drugs Sales Growth
4.6 Middle East & Africa Long-acting EPO Drugs Sales Growth
5 Americas
5.1 Americas Long-acting EPO Drugs Sales by Country
5.1.1 Americas Long-acting EPO Drugs Sales by Country (2018-2023)
5.1.2 Americas Long-acting EPO Drugs Revenue by Country (2018-2023)
5.2 Americas Long-acting EPO Drugs Sales by Type
5.3 Americas Long-acting EPO Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting EPO Drugs Sales by Region
6.1.1 APAC Long-acting EPO Drugs Sales by Region (2018-2023)
6.1.2 APAC Long-acting EPO Drugs Revenue by Region (2018-2023)
6.2 APAC Long-acting EPO Drugs Sales by Type
6.3 APAC Long-acting EPO Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Long-acting EPO Drugs by Country
7.1.1 Europe Long-acting EPO Drugs Sales by Country (2018-2023)
7.1.2 Europe Long-acting EPO Drugs Revenue by Country (2018-2023)
7.2 Europe Long-acting EPO Drugs Sales by Type
7.3 Europe Long-acting EPO Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Long-acting EPO Drugs by Country
8.1.1 Middle East & Africa Long-acting EPO Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Long-acting EPO Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Long-acting EPO Drugs Sales by Type
8.3 Middle East & Africa Long-acting EPO Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting EPO Drugs
10.3 Manufacturing Process Analysis of Long-acting EPO Drugs
10.4 Industry Chain Structure of Long-acting EPO Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting EPO Drugs Distributors
11.3 Long-acting EPO Drugs Customer
12 World Forecast Review for Long-acting EPO Drugs by Geographic Region
12.1 Global Long-acting EPO Drugs Market Size Forecast by Region
12.1.1 Global Long-acting EPO Drugs Forecast by Region (2024-2029)
12.1.2 Global Long-acting EPO Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Long-acting EPO Drugs Forecast by Type
12.7 Global Long-acting EPO Drugs Forecast by Application
13 Key Players Analysis
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Long-acting EPO Drugs Product Portfolios and Specifications
13.1.3 Amgen Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Long-acting EPO Drugs Product Portfolios and Specifications
13.2.3 Johnson & Johnson Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Kyowa Kirin
13.3.1 Kyowa Kirin Company Information
13.3.2 Kyowa Kirin Long-acting EPO Drugs Product Portfolios and Specifications
13.3.3 Kyowa Kirin Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Kyowa Kirin Main Business Overview
13.3.5 Kyowa Kirin Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global Long-acting EPO Drugs market size was valued at US$ 824.7 million in 2022. With growing demand in downstream market, the Long-acting EPO Drugs is forecast to a readjusted size of US$ 1111.5 million by 2029 with a CAGR of 4.4% during review period.
The research report highlights the growth potential of the global Long-acting EPO Drugs market. Long-acting EPO Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Long-acting EPO Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Long-acting EPO Drugs market.
Long-acting erythropoietin (EPO) drugs are a type of medication used to stimulate the production of red blood cells in the body. These drugs are primarily prescribed for individuals with certain medical conditions, such as anemia associated with chronic kidney disease or cancer treatment.
Key Features:
The report on Long-acting EPO Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Long-acting EPO Drugs market. It may include historical data, market segmentation by Type (e.g., Epoetin-alfa, Epoetin-beta), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Long-acting EPO Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Long-acting EPO Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Long-acting EPO Drugs industry. This include advancements in Long-acting EPO Drugs technology, Long-acting EPO Drugs new entrants, Long-acting EPO Drugs new investment, and other innovations that are shaping the future of Long-acting EPO Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Long-acting EPO Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Long-acting EPO Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Long-acting EPO Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Long-acting EPO Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Long-acting EPO Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Long-acting EPO Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Long-acting EPO Drugs market.
Market Segmentation:
Long-acting EPO Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Segmentation by application
Anemia
Kidney Disorders
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen
Johnson & Johnson
Kyowa Kirin
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting EPO Drugs market?
What factors are driving Long-acting EPO Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting EPO Drugs market opportunities vary by end market size?
How does Long-acting EPO Drugs break out type, application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Long-acting EPO Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Long-acting EPO Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Long-acting EPO Drugs by Country/Region, 2018, 2022 & 2029
2.2 Long-acting EPO Drugs Segment by Type
2.2.1 Epoetin-alfa
2.2.2 Epoetin-beta
2.2.3 Darbepoetin-alfa
2.2.4 Others
2.3 Long-acting EPO Drugs Sales by Type
2.3.1 Global Long-acting EPO Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Long-acting EPO Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Long-acting EPO Drugs Sale Price by Type (2018-2023)
2.4 Long-acting EPO Drugs Segment by Application
2.4.1 Anemia
2.4.2 Kidney Disorders
2.4.3 Others
2.5 Long-acting EPO Drugs Sales by Application
2.5.1 Global Long-acting EPO Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Long-acting EPO Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Long-acting EPO Drugs Sale Price by Application (2018-2023)
3 Global Long-acting EPO Drugs by Company
3.1 Global Long-acting EPO Drugs Breakdown Data by Company
3.1.1 Global Long-acting EPO Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Long-acting EPO Drugs Sales Market Share by Company (2018-2023)
3.2 Global Long-acting EPO Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Long-acting EPO Drugs Revenue by Company (2018-2023)
3.2.2 Global Long-acting EPO Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Long-acting EPO Drugs Sale Price by Company
3.4 Key Manufacturers Long-acting EPO Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting EPO Drugs Product Location Distribution
3.4.2 Players Long-acting EPO Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Long-acting EPO Drugs by Geographic Region
4.1 World Historic Long-acting EPO Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Long-acting EPO Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Long-acting EPO Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Long-acting EPO Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Long-acting EPO Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Long-acting EPO Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Long-acting EPO Drugs Sales Growth
4.4 APAC Long-acting EPO Drugs Sales Growth
4.5 Europe Long-acting EPO Drugs Sales Growth
4.6 Middle East & Africa Long-acting EPO Drugs Sales Growth
5 Americas
5.1 Americas Long-acting EPO Drugs Sales by Country
5.1.1 Americas Long-acting EPO Drugs Sales by Country (2018-2023)
5.1.2 Americas Long-acting EPO Drugs Revenue by Country (2018-2023)
5.2 Americas Long-acting EPO Drugs Sales by Type
5.3 Americas Long-acting EPO Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting EPO Drugs Sales by Region
6.1.1 APAC Long-acting EPO Drugs Sales by Region (2018-2023)
6.1.2 APAC Long-acting EPO Drugs Revenue by Region (2018-2023)
6.2 APAC Long-acting EPO Drugs Sales by Type
6.3 APAC Long-acting EPO Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Long-acting EPO Drugs by Country
7.1.1 Europe Long-acting EPO Drugs Sales by Country (2018-2023)
7.1.2 Europe Long-acting EPO Drugs Revenue by Country (2018-2023)
7.2 Europe Long-acting EPO Drugs Sales by Type
7.3 Europe Long-acting EPO Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Long-acting EPO Drugs by Country
8.1.1 Middle East & Africa Long-acting EPO Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Long-acting EPO Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Long-acting EPO Drugs Sales by Type
8.3 Middle East & Africa Long-acting EPO Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting EPO Drugs
10.3 Manufacturing Process Analysis of Long-acting EPO Drugs
10.4 Industry Chain Structure of Long-acting EPO Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting EPO Drugs Distributors
11.3 Long-acting EPO Drugs Customer
12 World Forecast Review for Long-acting EPO Drugs by Geographic Region
12.1 Global Long-acting EPO Drugs Market Size Forecast by Region
12.1.1 Global Long-acting EPO Drugs Forecast by Region (2024-2029)
12.1.2 Global Long-acting EPO Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Long-acting EPO Drugs Forecast by Type
12.7 Global Long-acting EPO Drugs Forecast by Application
13 Key Players Analysis
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Long-acting EPO Drugs Product Portfolios and Specifications
13.1.3 Amgen Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Long-acting EPO Drugs Product Portfolios and Specifications
13.2.3 Johnson & Johnson Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Kyowa Kirin
13.3.1 Kyowa Kirin Company Information
13.3.2 Kyowa Kirin Long-acting EPO Drugs Product Portfolios and Specifications
13.3.3 Kyowa Kirin Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Kyowa Kirin Main Business Overview
13.3.5 Kyowa Kirin Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/06/21 10:26

160.10 円

171.83 円

205.37 円

ページTOPに戻る